SEC Form 4	
FORM 4	UNITED STATES SECU

TATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287				
Estimated average burden					
hours per response:	0.5				

 \square

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					01 360	uon 30(n)		investment	COII	ірапу Асі	01 1940							
1. Name and Address of Reporting Person [*] Levinson Mitchell E.				2. Issuer Name and Ticker or Trading Symbol <u>Pulse Biosciences, Inc.</u> [PLSE]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 11/01/2023							C Officer below)	(give title hief Stra	tegy (Other (s below)				
3957 POINT EDEN WAY					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)														filed by One Reporting Person				
HAYWA	RD C	A	94545											Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)	F	Rule 10b5-1(c) Transaction Indication													
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intend the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									is intended to	satisfy								
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date			2. Transac Date (Month/Da	Execution Date		e, Transaction Disposed Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 aı		5. Amoun Securities Beneficia Owned Fe Reported	s Form ally (D) of ollowing (I) (In		Direct Indirect Estr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
							Code	v	Amount	(A) (D)	Price	Transacti	nsaction(s) str. 3 and 4)			115(1. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
Derivative Conversion Date E Security or Exercise (Month/Day/Year) if		3A. Deemed Execution Da if any (Month/Day/Y	Code	action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	011(5)			
Stock Option (right to buy)	\$4.38	11/01/2023		Α		100,000		(1)	11	1/01/2033	Common Stock	100,000	\$0	100,000		D		

Explanation of Responses:

1. 100% vesting upon the earlier of (i) the six (6) year anniversary of the grant date, and (ii) the 1-year anniversary of a Company change of control.

/s/ Kenneth B. Stratton, as	
Attorney-in-Fact	

<u>11/03/2023</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.